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hel lenic- journal-of-cardiology/PRESIDENT’S PAGEAcute coronary syndromes and atrial fibrillationAtrial fibrillation is the most common sustained cardiac
arrhythmia and affects 1.5%e2% of the general population.
More than six million Europeans suffer from atrial fibrilla-
tion, and the incidence of atrial fibrillation is estimated to
double over the next 50 years. The incidence of atrial
fibrillation increases with age, from <0.5% at 40 to 50 years
old, up to 5% to 15% at 80 years old. Men suffer more often
than women from atrial fibrillation. It is estimated that
more than 8 million patients over 80 years old will be
affected by atrial fibrillation in 2050. Atrial fibrillation is
associated with an increased risk of stroke, heart failure
and death, as well as a deterioration in the quality of life.1
Atrial fibrillation, permanent or paroxysmal, is common
in patients with acute coronary syndrome. The associated
mechanisms for the development of atrial fibrillation in
these patients includes ischemia and reduced atrial blood
flow, increased left ventricle end-diastolic pressure and
left atrial pressure, diastolic dysfunction and disorders of
the autonomic nervous system. Recently, inflammation and
neurohormonal activation mechanisms appear to be asso-
ciated with the development of atrial fibrillation in patients
with acute myocardial infarction. The incidence of atrial
fibrillation in acute coronary syndromes ranges from 2% to
23%. Recently, a downward trend in the incidence of atrial
fibrillation in patients with acute coronary syndromes has
been observed and this could be explained by the wide-
spread use of thrombolytic therapy and percutaneous cor-
onary interventions (PCI). The primary clinical prognostic
markers of risk for atrial fibrillation in patients with acute
coronary syndromes are advanced age, tachycardia on
admission and advanced heart failure.2
Atrial fibrillation increases the risk of worsening
ischemia, heart failure and thromboembolic complications.
Patients with acute coronary syndromes who developed
atrial fibrillation, have increased in-hospital and long-term
mortality. In a large meta-analysis that included 278,854
patients with myocardial infarction by 43 trials, atrial
fibrillation was associated with a 40% increase in the risk of
death compared to patients with sinus rhythms. Moreover,Peer review under responsibility of Hellenic Cardiological
Society.
http://dx.doi.org/10.1016/j.hjc.2016.05.001
1109-9666/ª 2016 Hellenic Cardiological Society. Publishing services by
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).atrial fibrillation was associated with increased risk of in-
hospital and long-term mortality, irrespective of the time
of occurrence, i.e., whether it was new onset or chronic.3
However, in a different meta-analysis, new onset atrial
fibrillation in patients with acute myocardial infarction was
associated with an 87% increase in in-hospital mortality risk
compared to patients with pre-existing atrial fibrillation.4
Atrial fibrillation leads to a number of hemodynamic
changes, such as loss of atrial contraction, rapid ventricular
rate and the loss of atrioventricular synchrony. These
changes cause a decrease in cardiac output, which may
explain the increased risk of death.5
Patients with atrial fibrillation with a fast ventricular
response may experience angina or discomfort and
elevated troponin levels, complicating the differential
diagnosis of acute coronary syndromes. In a large retro-
spective observational study of patients with atrial fibril-
lation, 9.2% of patients had elevated levels of high-
sensitivity troponin I, and this percentage may be even
higher in acute onset atrial fibrillation.6 Changes of
troponin in patients with atrial fibrillation and rapid ven-
tricular response may mimic myocardial infarction type 1.
In cases with very high troponin levels, the possibility of
myocardial infarction type 1 is high, and the performance
of coronary angiography is justified. In contrast, in the
majority of cases of atrial fibrillation and increased
troponin levels we suggest an ischemia detection test.7
Treatment of atrial fibrillation in patients with acute
coronary syndromes depends on the duration of
arrhythmia, the heart rate and the hemodynamic and
functional status of patients. Based on the above criteria,
different therapeutic approaches are needed, such as
administration of antiarrhythmic drugs for controlling the
heart rate, pharmaceutical cardioversion, or direct elec-
trical cardioversion in patients with hemodynamic
instability.8
Patients with acute coronary syndromes requires dual
antiplatelet therapy with aspirin and a second agent, such
as clopidogrel, and optional (depending on the CHA2DS2-
VASc score) addition of a vitamin K antagonist or a newer
oral anticoagulant factor (NOACs) when atrial fibrillation
coexists (triple antithrombotic therapy). The duration ofElsevier B.V. This is an open access article under the CC BY-NC-ND
142 President’s pagetriple antithrombotic therapy increases the risk of bleeding
complications and should be as short as possible, depending
on the hemorrhagic and ischemic risk and the possibility of
a PCI. The use of ticagrelor or prasugrel as part of the triple
antithrombotic therapy is not recommended because there
are no data on its safety and effectiveness in triple
therapy.9
For patients requiring long term oral anticoagulation and
are going to have PCI, there is insufficient data on the se-
lection of the appropriate type of stent. When the hemor-
rhagic risk is low (HAS-BLED score 2), using new
generation coated stents (DES) is recommended. When
there is high bleeding risk (HAS-BLED score 3), the choice
between bare metal stent (BMS) and new-generation DES
should be individualized. In patients with acute coronary
syndrome treated with oral anticoagulants (vitamin K an-
tagonists or NOACs) due to atrial fibrillation, PCI should be
performed without interruption of anticoagulation; there-
fore, radial access should be preferred. In patients treated
with vitamin K antagonists, if the INR is above 2.5, heparin
should not be administered. Conversely, if the patients take
NOACs, a small dose of intravenous heparin dose should be
used.7
Atrial fibrillation is a common co-morbidity in patients
with acute coronary syndromes and is an independent risk
factor for adverse cardiovascular events. Oral anticoagu-
lants are superior to antiplatelet therapy for preventing
stroke in atrial fibrillation, while the dual antiplatelet
therapy is indicated for acute coronary syndromes. The
triple antithrombotic therapy consisting of an anticoagu-
lant, aspirin and clopidogrel is recommended in patients
with acute coronary syndromes and atrial fibrillation,
although there is insufficient data from randomized clinical
trials. The ischemic and hemorrhagic risk should be esti-
mated, and the treatment should be chosen, with an
optimal balance between benefit and risk.
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